Last reviewed · How we verify

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

Arcutis Biotherapeutics, Inc. · Phase 3 active Small molecule

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% is a Aryl hydrocarbon receptor (AhR) agonist Small molecule drug developed by Arcutis Biotherapeutics, Inc.. It is currently in Phase 3 development for Atopic dermatitis, Plaque psoriasis. Also known as: Roflumilast.

ARQ-151 is a selective aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation.

ARQ-151 is a selective aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation. Used for Atopic dermatitis, Plaque psoriasis.

At a glance

Generic nameARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
Also known asRoflumilast
SponsorArcutis Biotherapeutics, Inc.
Drug classAryl hydrocarbon receptor (AhR) agonist
TargetAhR (Aryl hydrocarbon receptor)
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

ARQ-151 activates the aryl hydrocarbon receptor, a nuclear receptor involved in immune homeostasis and barrier function. By engaging AhR in skin immune cells, it promotes anti-inflammatory pathways and enhances skin barrier integrity, making it suitable for inflammatory skin conditions. This mechanism allows localized immunomodulation without systemic immunosuppression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

What is ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%?

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% is a Aryl hydrocarbon receptor (AhR) agonist drug developed by Arcutis Biotherapeutics, Inc., indicated for Atopic dermatitis, Plaque psoriasis.

How does ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% work?

ARQ-151 is a selective aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation.

What is ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% used for?

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% is indicated for Atopic dermatitis, Plaque psoriasis.

Who makes ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%?

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% is developed by Arcutis Biotherapeutics, Inc. (see full Arcutis Biotherapeutics, Inc. pipeline at /company/arcutis-biotherapeutics-inc).

Is ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% also known as anything else?

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% is also known as Roflumilast.

What drug class is ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% in?

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% belongs to the Aryl hydrocarbon receptor (AhR) agonist class. See all Aryl hydrocarbon receptor (AhR) agonist drugs at /class/aryl-hydrocarbon-receptor-ahr-agonist.

What development phase is ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% in?

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% is in Phase 3.

What are the side effects of ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%?

Common side effects of ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% include Application site irritation, Application site erythema, Pruritus.

What does ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% target?

ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% targets AhR (Aryl hydrocarbon receptor) and is a Aryl hydrocarbon receptor (AhR) agonist.

Related